Literature DB >> 1477437

Mathematical examination of dual individualization principles. (III): Development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients.

A Luzier1, T F Goss, T J Cumbo, J J Schentag.   

Abstract

OBJECTIVE: In order to quantitatively express the important, time-related aspects of response to antimicrobial therapy in patients with pneumonia, we required validated measures of the time course of events during the infection. To quantitate the changes in clinical status in relation to changes in cultures, we developed a scoring system to be used for patient assessment during therapy.
DESIGN: Retrospective data collection, prospective analysis of factors.
SETTING: Intensive care unit, Millard Fillmore Hospital. PATIENTS: Twenty-eight patients with nosocomial pneumonia. MAIN OUTCOME MEASURES: Clinical parameters were assessed daily for the duration of antimicrobial therapy. Using linear regression, the rate of clinical change in each patient treated was quantified. Eradication of the pathogen was determined by serial cultures of the infection site.
RESULTS: Seventeen of the patients demonstrated eradication of the organism, and 11 demonstrated persistence of the pathogen (7 were considered colonization). The system described the patients at baseline in that the mean baseline scores were similar in both groups of patients (p = 0.79). Patients in whom the pathogen was eradicated showed a rate of clinical improvement significantly different from those who had persistence of the organism (p = 0.04). In patients demonstrating eradication, the time to eradication inversely correlated with the rate of clinical improvement (p < 0.05). Of the ten parameters descriptive of the disease, those most sensitive to change after eradication of bacteria were body temperature, bacterial Gram stain, white blood cell Gram stain, and volume of sputum.
CONCLUSIONS: In this set of pneumonia patients, the scoring system effectively quantified both baseline and time-related changes in clinical status. The system distinguished between the clinical course of the patient with organism eradication versus organism persistence. A shorter time to eradication was associated with a better clinical response. Prospective study of the system will determine its sensitivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477437     DOI: 10.1177/106002809202601103

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

3.  Modeling the response of pneumonia to antimicrobial therapy.

Authors:  J M Hyatt; A B Luzier; A Forrest; C H Ballow; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

Authors:  H G Schaefer; H Stass; J Wedgwood; B Hampel; C Fischer; J Kuhlmann; U B Schaad
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 5.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

6.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.